Who’s driving? Switch of drivers in immunotherapy‐treated progressing sinonasal melanoma

7Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Mucosal melanoma can be driven by various driver mutations in genes such as NRAS, KIT, or KRAS. However, some cases present with only weak drivers, or lacking known oncogenic drivers, suggesting immunotherapy over targeted therapy. While resistance mechanisms to immu-notherapy in cutaneous melanoma have been uncovered, including alterations in JAK1/2, B2M, or STK11, a switch of oncogenic drivers under immunotherapy has not yet been observed. We report three cases of metastatic sinonasal melanoma that switched oncogenic drivers from KRAS, KIT, or no driver to NRAS during or after immunotherapy, thereby showing progressive disease. One of the cases presented with three spatially separate driver mutations in the primary tumor, whereas the NRAS clone persisted under immunotherapy. In comparison, three different control cases receiving radiotherapy only did not show a change of the detectable molecular drivers in their respec-tive recurrences or metastases. In summary, these data provide an important rationale for longitu-dinal molecular testing, based on evidence for an unforeseen recurrent event of molecular driver switch to NRAS in progressing sinonasal melanoma. These findings provide the basis for further studies on a potential causal relation of emerging NRAS mutant clones and immunotherapy.

Cite

CITATION STYLE

APA

Freiberger, S. N., Turko, P., Hüllner, M., Dummer, R., Morand, G. B., Levesque, M. P., … Rupp, N. J. (2021). Who’s driving? Switch of drivers in immunotherapy‐treated progressing sinonasal melanoma. Cancers, 13(11). https://doi.org/10.3390/cancers13112725

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free